Published in Int J Alzheimers Dis on March 25, 2012
Self-reported memory complaints: implications from a longitudinal cohort with autopsies. Neurology (2014) 2.66
Adjusting for mortality when identifying risk factors for transitions to mild cognitive impairment and dementia. J Alzheimers Dis (2013) 0.97
Self-reported head injury and risk of late-life impairment and AD pathology in an AD center cohort. Dement Geriatr Cogn Disord (2013) 0.86
Effect of common neuropathologies on progression of late life cognitive impairment. Neurobiol Aging (2015) 0.85
Repeated retrieval during working memory is sensitive to amnestic mild cognitive impairment. J Clin Exp Neuropsychol (2013) 0.78
A Summary Score for the Framingham Heart Study Neuropsychological Battery. J Aging Health (2015) 0.77
Markov chains and semi-Markov models in time-to-event analysis. J Biom Biostat (2013) 0.75
A Late Life Risk Index for Severe Cognitive Impairment in Mexico. J Alzheimers Dis (2016) 0.75
Outcomes after diagnosis of mild cognitive impairment in a large autopsy series. Ann Neurol (2017) 0.75
Are Markov and semi-Markov models flexible enough for cognitive panel data? J Biom Biostat (2013) 0.75
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology (1984) 119.59
Mild cognitive impairment as a diagnostic entity. J Intern Med (2004) 26.95
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology (1993) 16.92
Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med (2004) 16.58
The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord (2006) 8.04
Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement (2005) 7.90
Neuropathologic substrate of mild cognitive impairment. Arch Neurol (2006) 6.26
The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis Assoc Disord (2009) 5.50
Mild cognitive impairment is not a clinical entity and should not be treated. Arch Neurol (2005) 4.26
Mild cognitive impairment, amnestic type: an epidemiologic study. Neurology (2004) 3.94
Classification criteria for mild cognitive impairment: a population-based validation study. Neurology (2001) 3.92
Baseline and longitudinal patterns of brain atrophy in MCI patients, and their use in prediction of short-term conversion to AD: results from ADNI. Neuroimage (2008) 3.74
Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol (2005) 3.69
"Preclinical" AD revisited: neuropathology of cognitively normal older adults. Neurology (2000) 3.57
Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. Arch Neurol (2003) 3.47
Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. Curr Alzheimer Res (2009) 3.31
Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles "do count" when staging disease severity. J Neuropathol Exp Neurol (2007) 2.65
Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer's Disease. J Neurol Neurosurg Psychiatry (2006) 2.48
Framingham stroke risk profile and lowered cognitive performance. Stroke (2004) 2.46
Amnestic MCI or prodromal Alzheimer's disease? Lancet Neurol (2004) 2.29
Relationship of vascular risk to the progression of Alzheimer disease. Neurology (2006) 2.08
Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with Alzheimer dementia: the Cache County Dementia Progression study. Am J Geriatr Psychiatry (2011) 1.83
Variations in case definition affect prevalence but not outcomes of mild cognitive impairment. Neurology (2003) 1.82
Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons. Neurology (2009) 1.78
Mild cognitive impairment in the general population: occurrence and progression to Alzheimer disease. Am J Geriatr Psychiatry (2008) 1.77
Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology (2007) 1.67
Identification of conversion from mild cognitive impairment to Alzheimer's disease using multivariate predictors. PLoS One (2011) 1.66
Measuring Alzheimer's disease progression with transition probabilities: estimates from CERAD. Neurology (2001) 1.60
The effects of intelligence and education on the development of dementia. A test of the brain reserve hypothesis. Psychol Med (1997) 1.57
The concept of cognitive reserve: a catalyst for research. J Clin Exp Neuropsychol (2003) 1.51
Risk factors for transitions from normal to mild cognitive impairment and dementia. Neurology (2006) 1.46
Brain donation in normal aging: procedures, motivations, and donor characteristics from the Biologically Resilient Adults in Neurological Studies (BRAiNS) Project. Gerontologist (2001) 1.45
Shared random effects analysis of multi-state Markov models: application to a longitudinal study of transitions to dementia. Stat Med (2007) 1.36
The effects of age on rate of progression of Alzheimer disease and dementia with associated cerebrovascular disease. Arch Neurol (2001) 1.35
The APOE epsilon4 allele is associated with incident mild cognitive impairment among community-dwelling older persons. Neuroepidemiology (2009) 1.35
Testing the white matter retrogenesis hypothesis of cognitive aging. Neurobiol Aging (2011) 1.15
Brain reserve and the clinical expression of Alzheimer's disease. Geriatrics (1997) 1.11
Progression of mild cognitive impairment to dementia: a challenge to current thinking. Br J Psychiatry (2006) 1.10
Is the apolipoprotein e genotype a biomarker for mild cognitive impairment? Findings from a nationally representative study. Neuropsychology (2011) 1.03
What is mild cognitive impairment? Variations in definitions and evolution of nondemented persons with cognitive impairment. Acta Neurol Scand Suppl (2003) 1.01
Preclinical AD Workgroup staging: pathological correlates and potential challenges. Neurobiol Aging (2011) 0.99
Clinical features of mild cognitive impairment differ in the research and tertiary clinic settings. Dement Geriatr Cogn Disord (2008) 0.96
No association between hypertension and risk for Alzheimer's disease: a meta-analysis of longitudinal studies. J Alzheimers Dis (2011) 0.95
Should mild cognitive impairment be subtyped? Curr Opin Psychiatry (2011) 0.95
Outcomes of incident mild cognitive impairment in relation to case definition. J Neurol Neurosurg Psychiatry (2005) 0.93
Early Alzheimer's disease. Diagnostic considerations. Arch Neurol (1988) 0.83
Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet (2005) 10.11
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
A combined computational-experimental approach predicts human microRNA targets. Genes Dev (2004) 9.82
Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol (2010) 8.74
Neuropathologic substrate of mild cognitive impairment. Arch Neurol (2006) 6.26
Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol (2006) 6.20
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10
Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging (2009) 4.36
The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J Neurosci (2008) 4.28
An mRNA m7G cap binding-like motif within human Ago2 represses translation. Cell (2007) 4.03
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res (2003) 3.71
Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell (2007) 3.37
Tooth loss, dementia and neuropathology in the Nun study. J Am Dent Assoc (2007) 3.29
Epithelial myosin light chain kinase-dependent barrier dysfunction mediates T cell activation-induced diarrhea in vivo. J Clin Invest (2005) 3.15
Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res (2005) 2.98
TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. J Neuropathol Exp Neurol (2007) 2.97
Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol Aging (2005) 2.97
Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res (2004) 2.73
Transitions to mild cognitive impairments, dementia, and death: findings from the Nun Study. Am J Epidemiol (2007) 2.70
Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles "do count" when staging disease severity. J Neuropathol Exp Neurol (2007) 2.65
Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg (2005) 2.53
Energizing miRNA research: a review of the role of miRNAs in lipid metabolism, with a prediction that miR-103/107 regulates human metabolic pathways. Mol Genet Metab (2007) 2.52
Salivary biomarkers of existing periodontal disease: a cross-sectional study. J Am Dent Assoc (2006) 2.48
Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons. Brain Pathol (2008) 2.44
Novel ubiquitin neuropathology in frontotemporal dementia with valosin-containing protein gene mutations. J Neuropathol Exp Neurol (2006) 2.43
Dicer loss in striatal neurons produces behavioral and neuroanatomical phenotypes in the absence of neurodegeneration. Proc Natl Acad Sci U S A (2008) 2.32
Predicting risk of malignancy in adnexal masses. Obstet Gynecol (2010) 2.31
Age and gender effects on human brain anatomy: a voxel-based morphometric study in healthy elderly. Neurobiol Aging (2006) 2.23
The miR-15/107 group of microRNA genes: evolutionary biology, cellular functions, and roles in human diseases. J Mol Biol (2010) 2.20
GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology (2012) 2.19
Hippocampal sclerosis in advanced age: clinical and pathological features. Brain (2011) 2.16
Depression, apolipoprotein E genotype, and the incidence of mild cognitive impairment: a prospective cohort study. Arch Neurol (2006) 2.13
Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J Pharmacol Exp Ther (2010) 2.09
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol (2010) 2.06
PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells. Cancer Biol Ther (2009) 1.97
Patterns of colorectal cancer incidence, risk factors, and screening in Kentucky. South Med J (2004) 1.94
Dissociation of automatic and strategic lexical-semantics: functional magnetic resonance imaging evidence for differing roles of multiple frontotemporal regions. J Neurosci (2006) 1.92
Antitumor activity of sphingosine kinase inhibitors. J Pharmacol Exp Ther (2006) 1.88
Bone remodeling biomarkers of periodontal disease in saliva. J Periodontol (2008) 1.88
Selecting treatment for patients with malignant epidural spinal cord compression-does age matter?: results from a randomized clinical trial. Spine (Phila Pa 1976) (2009) 1.79
Frequency and disposition of ovarian abnormalities followed with serial transvaginal ultrasonography. Obstet Gynecol (2013) 1.77
Clinical implications of a rising serum CA-125 within the normal range in patients with epithelial ovarian cancer: a preliminary investigation. Gynecol Oncol (2003) 1.75
Low sensitivity in clinical diagnoses of dementia with Lewy bodies. J Neurol (2009) 1.73
Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts. Cancer Biol Ther (2011) 1.72
Long-term survival of women with epithelial ovarian cancer detected by ultrasonographic screening. Obstet Gynecol (2011) 1.72
Suppression of ulcerative colitis in mice by orally available inhibitors of sphingosine kinase. Dig Dis Sci (2007) 1.72
Patterns of microRNA expression in normal and early Alzheimer's disease human temporal cortex: white matter versus gray matter. Acta Neuropathol (2010) 1.71
A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. J Neuroinflammation (2007) 1.70
Brains with medial temporal lobe neurofibrillary tangles but no neuritic amyloid plaques are a diagnostic dilemma but may have pathogenetic aspects distinct from Alzheimer disease. J Neuropathol Exp Neurol (2009) 1.66
Lifelong bilingualism maintains neural efficiency for cognitive control in aging. J Neurosci (2013) 1.62
Protein kinase involved in lung injury susceptibility: evidence from enzyme isoform genetic knockout and in vivo inhibitor treatment. Proc Natl Acad Sci U S A (2003) 1.62
Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies. Acta Neuropathol (2011) 1.62
Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened. Cancer (2007) 1.61
Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. Cancer Res (2004) 1.59
The search for meaning-Symptoms and transvaginal sonography screening for ovarian cancer: predicting malignancy. Cancer (2009) 1.59
Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res (2007) 1.58
Clinical studies in familial VCP myopathy associated with Paget disease of bone and frontotemporal dementia. Am J Med Genet A (2008) 1.57
Suppression of acute proinflammatory cytokine and chemokine upregulation by post-injury administration of a novel small molecule improves long-term neurologic outcome in a mouse model of traumatic brain injury. J Neuroinflammation (2008) 1.57
Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases. Cancer Res (2006) 1.56
miR-107 regulates granulin/progranulin with implications for traumatic brain injury and neurodegenerative disease. Am J Pathol (2010) 1.54
Inflammatory cytokines stimulate the chemokines CCL2/MCP-1 and CCL7/MCP-3 through NFkB and MAPK dependent pathways in rat astrocytes [corrected]. Brain Res (2009) 1.53
University of Kentucky Sanders-Brown healthy brain aging volunteers: donor characteristics, procedures and neuropathology. Curr Alzheimer Res (2012) 1.52
Does the arousal system contribute to near death experience? Neurology (2006) 1.50